Gary Remington, MD, PhD, FRCPC

JCP
Meta-Analysis

March 6, 2018

Case reports suggest psychosis might worsen with a switch to or addition of aripiprazole. But is worsening just as likely with other antipsychotics? To answer this question, this government-supported...
Hiroyoshi Takeuchi, Ali Fathi, Sadhana Thiyanavadivel, et al
JCP
Original Research

November 14, 2017

Valbenazine, a VMAT2  inhibitor, is approved for the treatment of tardive dyskinesia. However, its long-term safety and efficacy have not been reported. This extension of the KINECT 3 study...
Stewart A. Factor, Gary Remington, Cynthia L. Comella, et al
JCP
Article

February 22, 2017

What's the best way to switch to clozapine in patients with treatment-resistant schizophrenia? Do you worry that efficacy and tolerability will be compromised? This pilot, double-blind RCT addresses your...
Hiroyoshi Takeuchi, Jimmy Lee, Gagan Fervaha, et al
JCP
Article

May 25, 2016

Clozapine is the most effective antipsychotic used in the treatment of refractory schizophrenia. But how do factors like smoking and caffeine intake affect plasma clozapine levels? The authors of...
Jimmy Lee, Robert Bies, Hiroyoshi Takeuchi, et al
JCP
Letter to the Editor

April 27, 2016

Jimmy Lee, Gary Remington
JCP
Original Research

January 27, 2016

Carol Borlido, Gary Remington, Ariel Graff-Guerrero, et al
JCP
Original Research

December 23, 2015

Jimmy Lee, Robert Bies, Amaal Bhaloo, et al
JCP
Original Research

July 22, 2015

Gagan Fervaha, Hiroyoshi Takeuchi, Ofer Agid, et al
JCP
Original Research

January 28, 2015

Mark Sinyor, Ayal Schaffer, Gary Remington
JCP
Original Research

July 22, 2014

Hiroyoshi Takeuchi, Takefumi Suzuki, Robert R. Bies, et al
JCP
Original Research

May 15, 2014

Hiroyoshi Takeuchi, Gagan Fervaha, Hiroyuki Uchida, et al
JCP
Article

August 15, 2012

Saeko Ikai, Gary Remington, Takefumi Suzuki, et al

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe